Bright! FRONTEO Official Blog

Bright! FRONTEO Official Blog

[Webinar held on 6/15] New AI solution "liGALILEO" for multifaceted scientific evaluation of target molecules-Realizing efficient drug discovery development-

The development of new drugs can be broadly divided into "target search" to search for candidate molecules in the initial phase, "non-clinical studies" using animals, and "clinical studies" to verify efficacy and safety by actually administering to humans. There are three processes, but only 3 / 2 to 3 / 1 of the candidate compounds that are considered to be promising in the initial phase are commercialized, and in addition, they last for a long period of 10 to 15 years. The development period and the enormous development cost of about 1000 billion yen have been regarded as major issues in drug development.
In this seminar, FRONTEO's unique AI technology can be used to perform multifaceted scientific evaluation of candidate substances, enabling the digitization and overwhelming efficiency of the search process, which is important in the initial phase of drug development. Introducing the new AI solution "liGALILEO".

Click here for details on application and seminars:

【Webinar Summary】

◆ Theme: New AI solution "liGALILEO" for multifaceted scientific evaluation of target molecules-Realizing efficient drug discovery development-

◆ Date: May 2022, 6 (Wednesday) 15: 12-10: 12

◆ Recommended for people like this!
・ Those who work for a pharmaceutical company
・ Those who are considering improving the efficiency of the drug discovery process with AI
・ Those involved in drug discovery research

◆ Participation conditions: Those who use free addresses, those who are in the same industry as our company, and those whose affiliation is unknown are not allowed to apply.When accessing ZOOM on the day of the event, please enter the name and email address you provided when you applied for the ZOOM participation input field.

FRONTEO Inc. Life Science AI Business Headquarters Business Development Team General Manager
Keiichiro Yoshimoto

After joining Mitsubishi Tanabe Pharma (formerly Mitsubishi Tanabe Pharma), he engaged in overseas business development and was in charge of out-licensing and marketing of cardiovascular drugs in emerging regions centered on Asia.After that, he was in charge of domestic and overseas business development of functional chemicals at Kao and Sumitomo Chemical, and was assigned overseas as a sales manager. Since 2016, he has participated in the establishment of a pharmaceutical venture company and launched several new businesses as a business manager in the animal health field. He joined FRONTEO in 2021.He is currently working on new business development in the business development team of the Life Science AI Business Headquarters.

Articles in the same category

Commonly viewed articles

ja 日本語
Machine Translation by Google. : close x